EA201790655A1 - Новые активаторы растворимой гуанилатциклазы и их применение - Google Patents

Новые активаторы растворимой гуанилатциклазы и их применение

Info

Publication number
EA201790655A1
EA201790655A1 EA201790655A EA201790655A EA201790655A1 EA 201790655 A1 EA201790655 A1 EA 201790655A1 EA 201790655 A EA201790655 A EA 201790655A EA 201790655 A EA201790655 A EA 201790655A EA 201790655 A1 EA201790655 A1 EA 201790655A1
Authority
EA
Eurasian Patent Office
Prior art keywords
soluble
guanylatzclaze
application
activators
new activators
Prior art date
Application number
EA201790655A
Other languages
English (en)
Other versions
EA033697B1 (ru
Inventor
Анн Мари Жанн Буйо
Нерина Додик
Original Assignee
Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед filed Critical Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед
Publication of EA201790655A1 publication Critical patent/EA201790655A1/ru
Publication of EA033697B1 publication Critical patent/EA033697B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

Изобретение относится к активаторам растворимой гуанилатциклазы и к их применению в фармацевтических композициях, главным образом офтальмологических композициях для местного применения. Фармацевтические композиции применимы для снижения внутриглазного давления у животных видов млекопитающих.
EA201790655A 2014-09-19 2015-09-18 Активаторы растворимой гуанилатциклазы и их применение EA033697B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462052537P 2014-09-19 2014-09-19
PCT/IB2015/057219 WO2016042536A1 (en) 2014-09-19 2015-09-18 Novel soluble guanylate cyclase activators and their use

Publications (2)

Publication Number Publication Date
EA201790655A1 true EA201790655A1 (ru) 2017-08-31
EA033697B1 EA033697B1 (ru) 2019-11-18

Family

ID=54238488

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790655A EA033697B1 (ru) 2014-09-19 2015-09-18 Активаторы растворимой гуанилатциклазы и их применение

Country Status (21)

Country Link
US (2) US9938260B2 (ru)
EP (1) EP3194384A1 (ru)
JP (3) JP6678656B2 (ru)
KR (1) KR20170054508A (ru)
CN (1) CN106687456B (ru)
AU (1) AU2015319724B2 (ru)
BR (1) BR112017005660A2 (ru)
CA (1) CA2961745A1 (ru)
CL (1) CL2017000640A1 (ru)
CO (1) CO2017002506A2 (ru)
CR (1) CR20170102A (ru)
DO (1) DOP2017000073A (ru)
EA (1) EA033697B1 (ru)
IL (1) IL251094A0 (ru)
MA (1) MA40583A (ru)
MX (1) MX2017003621A (ru)
PE (1) PE20170937A1 (ru)
PH (1) PH12017500481A1 (ru)
SG (1) SG11201701915TA (ru)
WO (1) WO2016042536A1 (ru)
ZA (1) ZA201701835B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109851610B (zh) 2014-02-06 2021-09-21 赫普泰雅治疗有限公司 作为毒蕈碱m1和/或m4受体激动剂的双环氮杂化合物
PE20170697A1 (es) 2014-09-19 2017-06-24 Bayer Pharma AG Indazoles sustituidos con benzilo como inhibidores de bub1
EP3194384A1 (en) * 2014-09-19 2017-07-26 GlaxoSmithKline Intellectual Property Development Limited Novel soluble guanylate cyclase activators and their use
CN109890379A (zh) 2016-10-11 2019-06-14 拜耳制药股份公司 包含sGC活化剂和盐皮质激素受体拮抗剂的组合产品
WO2019081456A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
EP3498298A1 (en) 2017-12-15 2019-06-19 Bayer AG The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi)
US20210052528A1 (en) 2018-04-30 2021-02-25 Bayer Aktiengesellschaft The use of sgc activators and sgc stimulators for the treatment of cognitive impairment
CN112384213A (zh) 2018-05-15 2021-02-19 拜耳公司 用于治疗与神经纤维敏化有关的疾病的1,3-噻唑-2-基取代的苯甲酰胺
EP3574905A1 (en) 2018-05-30 2019-12-04 Adverio Pharma GmbH Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group
WO2020148379A1 (en) 2019-01-17 2020-07-23 Bayer Aktiengesellschaft Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc)
WO2023237577A1 (en) 2022-06-09 2023-12-14 Bayer Aktiengesellschaft Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602143A (en) 1994-12-08 1997-02-11 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors
CA2668814A1 (en) 2006-11-09 2008-06-05 Alcon Research, Ltd. Water insoluble polymer matrix for drug delivery
WO2009071504A1 (en) * 2007-12-03 2009-06-11 Smithkline Beecham Corporation 2,6-disubstituted pyridines as soluble guanylate cyclase activators
WO2010015653A1 (en) 2008-08-07 2010-02-11 Smithkline Beecham Corporation Pyrimidine derivatives as activators of soluble guanylate cyclase
BRPI1008793A2 (pt) * 2009-02-26 2016-03-08 Merck Sharp & Dohme composto, uso de um composto, e, composição farmacêutica
DE102009012314A1 (de) * 2009-03-09 2010-09-16 Bayer Schering Pharma Aktiengesellschaft Oxo-heterocyclisch substituierte Alkylcarbonsäuren und ihre Verwendung
JP5636296B2 (ja) 2011-01-20 2014-12-03 公益財団法人微生物化学研究会 塩分含有有機廃液処理剤、並びに、塩分濃度低下剤、塩分含有有機廃液の処理方法、及び包括固定担体
EP3194384A1 (en) * 2014-09-19 2017-07-26 GlaxoSmithKline Intellectual Property Development Limited Novel soluble guanylate cyclase activators and their use

Also Published As

Publication number Publication date
EA033697B1 (ru) 2019-11-18
US20180194756A1 (en) 2018-07-12
JP6908747B2 (ja) 2021-07-28
CA2961745A1 (en) 2016-03-24
CN106687456B (zh) 2019-12-03
WO2016042536A1 (en) 2016-03-24
JP2021155450A (ja) 2021-10-07
KR20170054508A (ko) 2017-05-17
CL2017000640A1 (es) 2017-10-06
PH12017500481A1 (en) 2017-08-07
JP6678656B2 (ja) 2020-04-08
DOP2017000073A (es) 2017-04-16
CO2017002506A2 (es) 2017-07-28
JP2020105189A (ja) 2020-07-09
BR112017005660A2 (pt) 2017-12-19
SG11201701915TA (en) 2017-04-27
AU2015319724B2 (en) 2018-05-10
JP2017527602A (ja) 2017-09-21
IL251094A0 (en) 2017-04-30
MX2017003621A (es) 2017-07-14
US9938260B2 (en) 2018-04-10
CR20170102A (es) 2017-07-17
PE20170937A1 (es) 2017-07-13
CN106687456A (zh) 2017-05-17
US20170305888A1 (en) 2017-10-26
MA40583A (fr) 2016-03-24
US10472350B2 (en) 2019-11-12
ZA201701835B (en) 2018-12-19
AU2015319724A1 (en) 2017-04-06
EP3194384A1 (en) 2017-07-26

Similar Documents

Publication Publication Date Title
EA201790655A1 (ru) Новые активаторы растворимой гуанилатциклазы и их применение
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201691582A1 (ru) Новые фармацевтические препараты
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
NZ733055A (en) Anti-c10orf54 antibodies and uses thereof
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
EA201790248A1 (ru) Композиции носитель-антитело и способы их получения и применения
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
EA201691945A1 (ru) Антитела к гемагглютинину вируса гриппа типа b и способы их применения
EA201692552A1 (ru) МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
CL2015002897A1 (es) Inhibidores de bace1
EA201692474A1 (ru) Производные 1-(циклопент-2-ен-1-ил)-3-(2-гидрокси-3-(арилсульфонил)фенил)мочевины в качестве ингибиторов cxcr2
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
MX2020006596A (es) Hidroxiisoxazolinas y derivados de estos.
MX2017005975A (es) Anticuerpos anti factor de crecimiento derivado de plaquetas b (pdgf-b) y metodos de uso.
TR201820050T4 (tr) Bromodomain inhibitörleri olarak tetrahidrokinolin türevleri.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM